MorphoSys Inc (MOR) - Rasio rega marang prakiraan pendapatan
The market has already priced in the acquisition of MorphoSys AG (MOR) due to expectations surrounding its myelofibrosis drug. The business remains independent of GDP cycles, relying instead on clinical progress. Patent protection of molecules ensures a temporary monopoly. The company's projected P/S ratio helps assess valuation risks, while 12.90 serves as the current parameter value on this chart.
Rincian analitis perusahaan MorphoSys AG
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator beban utang lan likuiditas:
Utang marang Ekuitas MorphoSys AG|MOR - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas MorphoSys AG|MOR - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku MorphoSys Corporation|MOR - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan MorphoSys|Rasio cepet morphosys.com
- rincian asil keuangan lan kelipatan valuasi:
MOR - Bathi resik|Proyeksi bathi mangsa ngarep MorphoSys AG|MOR - Rasio kapitalisasi marang bathi resik|Rega marang bathi mangsa ngarep MorphoSys Corp|MOR - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan MorphoSys Corporation|MOR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan MorphoSys|MOR - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan morphosys.com|MOR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep MorphoSys AG
- statistik dodolan lan pendapatan perusahaan:
Analisis wiwitan perusahaan:MOR (MorphoSys)
The forward P/S reflects the ratio of MorphoSys AG (MOR) market capitalization to projected revenue, allowing for an assessment of the growth premium amid liquidity volatility. By analyzing the projected P/S of MorphoSys AG (MOR) on the GURU.Markets platform, an investor can compare the business valuation with the monetization potential of the HuCAL library via royalties, which determines the fundamental fairness of the asset's current quotes.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan BeiGene ONC|Rega forward marang dodolan HALO|RVMD - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan AAPG|CGON: Multiplikator Forward P/S|urogen.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Inc PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|aurabiosciences.com (AURA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CADL - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Accuray Inc ARAY|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|Actuate Therapeutics Inc - Rega forward marang dodolan|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S TuHURA|Multiplikator Forward P/S TARA|Fate Therapeutics Inc (FATE) - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|TCRX - Multiplikator forward rega marang pendapatan|CSBR - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep XBiotech Inc.|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|OS Therapies Inc. - Rega forward marang dodolan|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Artiva (ARTV)|Multiplikator Forward P/S ANL|Multiplikator Forward P/S verupharma.com (VERU)|Rasio rega marang prakiraan pendapatan Tempest Therapeutics, Inc. TPST|XLO: Kapitalisasi marang prakiraan pendapatan|Enochian BioSciences - Multiplikator Forward P/S|Mural Oncology plc (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OnKure Therapeutics (OKUR)|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Ltd|CRIS: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan APLM (Apollomics, Inc.)|THAR (Tharimmune Corporation) - Rega forward marang dodolan|Multiplikator Forward P/S ADVB (Advanced Biomed)|GNPX - Multiplikator forward rega marang pendapatan|CLDI: Multiplikator forward rega marang pendapatan|SBFM - Multiplikator Forward P/S|xeneticbio.com (XBIO) - Rasio rega marang prakiraan pendapatan|Salarius Pharma - Rega forward marang dodolan|PPBT (Purple Biotech) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AON AONC|Rasio rega marang prakiraan pendapatan BeiGene (BGNE)|Multiplikator forward rega marang pendapatan Checkpoint Therapeutics Inc. CKPT|Rasio rega marang prakiraan pendapatan Elevation Oncology, Inc. ELEV|iCAD Inc. (ICAD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IKNA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan NTBL (notablelabs.com)|viracta.com (VIRX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan NAYA (NAYA Biosciences Inc)|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
